Richard Paulson - Mar 4, 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
President and CEO, Director
Signature
/s/Nancy Smith as Attorney-in-Fact for Richard Paulson
Stock symbol
KPTI
Transactions as of
Mar 4, 2025
Transactions value $
-$73,555
Form type
4
Date filed
3/6/2025, 04:27 PM
Previous filing
Mar 4, 2025
Next filing
Apr 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$73.6K -11.7K -12.35% $6.29* 83K Mar 4, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.